Quick Reference
Reporting Criteria
Standardised scoring systems and response criteria used in PET reporting. Reference guides and visual graphics coming soon — organised by tracer and clinical application.
Deauville
PERCIST
miPSMA / PROMISE
Krenning Score
RANO-NM
Lugano Classification
📊
Visual Reference Graphics Coming Soon
Printable one-page graphics for each scoring system — Deauville 5-point scale, Krenning score, miPSMA, RANO-NM, and more. Designed to be kept at your workstation. Key guidelines and references are available now below.
FDG PET response assessment in lymphoma is governed by the Lugano Classification and Deauville 5-point scale. Liver is always the reference organ.
Visual Guide Coming Soon
Deauville 5-Point Scale
Score 1–5 based on uptake relative to mediastinum (scores 1–2) and liver (scores 3–5). Score 4–5 = residual disease. Used for interim and end-of-treatment assessment.
Mediastinum referenceLiver referenceInterim PETEnd of treatment
Visual Guide Coming Soon
Lugano Classification
Replaces Cheson 2007. Integrates PET and CT response criteria. Defines complete metabolic response (CMR), partial metabolic response (PMR), and progressive metabolic disease (PMD).
CMRPMRPMDCT + PET integrated
Key Guideline
Lugano Classification — Cheson et al, Journal of Clinical Oncology, 2014
The standard reference for lymphoma response criteria integrating PET and CT.
View →
PERCIST defines metabolic response in solid tumors using SULpeak measurements. RECIST 1.1 remains the anatomic complement — both are often reported together.
Visual Guide Coming Soon
PERCIST 1.0
PET Response Criteria in Solid Tumors. Uses SULpeak (lean body mass corrected SUV) of the most active lesion. Defines complete, partial, stable, and progressive metabolic disease.
SULpeakCMRPMR ≥30% decreasePMD ≥30% increase
Visual Guide Coming Soon
EORTC Criteria
Earlier metabolic response criteria using SUVmax. Still referenced in some trials. PERCIST is now preferred for most solid tumor applications.
SUVmax basedTrial useHistorical reference
Key Guideline
PERCIST — Wahl et al, Journal of Nuclear Medicine, 2009
The foundational paper defining metabolic response criteria for solid tumors.
View →
Krenning score quantifies DOTATATE uptake relative to liver at each disease site. All lesions must meet the threshold for PRRT eligibility — one low-avidity site excludes a patient.
Visual Guide Coming Soon
Krenning Score
1 = very low (less than liver), 2 = low (equal to liver), 3 = moderate (greater than liver), 4 = high (greater than spleen). Score ≥3 at all sites required for PRRT eligibility. Always use liver as reference — never spleen.
Score 1–4Liver referencePRRT eligibilityPer lesion scoring
Visual Guide Coming Soon
RECIST for NETs
Anatomic response criteria used alongside DOTATATE for treatment monitoring. SUV changes on DOTATATE after PRRT correlate with clinical outcome.
Post-PRRT monitoringCT complementSUV reduction
Key Guideline
SNMMI Procedure Standard — DOTATATE PET/CT, 2020
Patient selection criteria and reporting standards for somatostatin receptor PET.
View →
miPSMA (PROMISE) scoring quantifies PSMA expression at each lesion site. Required for Lu-177 PSMA eligibility assessment — all lesions must score ≥3.
Visual Guide Coming Soon
miPSMA Score (PROMISE)
Molecular Imaging TNM (miTNM) system. miPSMA scores 1–5: 1 = very low, 2 = low, 3 = intermediate, 4 = high, 5 = very high. Score ≥3 at all lesion sites required for PLUVICTO eligibility per VISION trial criteria.
Score 1–5PLUVICTO eligibilityVISION criteriaPer lesion
Visual Guide Coming Soon
miTNM Staging
Molecular imaging TNM system for prostate cancer. Classifies primary (miT), nodal (miN), and metastatic (miM) disease based on PSMA PET findings. Complements pathologic staging.
miT stagingmiN stagingmiM stagingBCR localisation
Key Guideline
PROMISE — Eiber et al, European Urology, 2018
The standardised framework for PSMA PET reporting and miPSMA scoring.
View →
Brain PET reporting criteria span multiple tracers and clinical applications — from amyloid visual reads to glioma response assessment.
Visual Guide Coming Soon
Amyloid PET Visual Read
Binary positive/negative visual read. Positive = loss of grey-white matter contrast with cortical tracer retention. Posterior cingulate and precuneus are the earliest and most sensitive regions.
Positive / NegativeGrey-white contrastPosterior cingulateCentiloid scale
Visual Guide Coming Soon
RANO-NM — Brain Tumor Response
Response Assessment in Neuro-Oncology for Nuclear Medicine. Uses TBR (tumour-to-background ratio) thresholds on amino acid PET. Defines complete, partial, and progressive metabolic disease for glioma.
TBRmax thresholdFET / FDOPAGlioma responsePseudoprogression
Visual Guide Coming Soon
Braak Staging — Tau PET
Six-stage framework describing the anatomical spread of tau pathology from medial temporal lobe (Braak I–II) through neocortex (Braak V–VI). Correlates with clinical severity.
Braak I–VIMTL spreadFlortaucipirClinical correlation
Key Guideline
RANO-NM Criteria — Galldiks et al, Lancet Oncology, 2021
Standardised response criteria for amino acid PET in neuro-oncology.
View →
Radioiodine therapy for differentiated thyroid cancer involves diagnostic ¹²³I scanning followed by ¹³¹I ablation. Response is assessed by thyroglobulin levels and post-therapy scan.
Visual Guide Coming Soon
Post-Therapy ¹³¹I Scan Reporting
Whole body scan 5–8 days post RAI ablation. Documents remnant thyroid tissue, locoregional disease, and distant metastases. Correlated with stimulated thyroglobulin.
¹³¹I RAIRemnant ablationThyroglobulinPost-therapy scan
Visual Guide Coming Soon
ATA Risk Stratification
American Thyroid Association risk stratification guides RAI use and follow-up intensity. Low, intermediate, and high risk categories determine whether ablation is indicated.
Low riskIntermediate riskHigh riskRAI indication
Key Guideline
ATA Guidelines — Thyroid Cancer Management, 2015
American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer.
View →